Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235844 | 0.91 | PTGDR2 (0.52) | PTGDR2KDM4EFFAR1HPGDTSHR | |
| SCHEMBL14026553 | 0.84 | NPC1 (0.50) | PTGDR2NPC1RAB9ATP53HSD17B10 | |
| SCHEMBL3951141 | 0.83 | PTGDR2 (0.67) | PTGDR2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL13515795 | 0.82 | NPC1 (0.70) | PTGDR2NPC1RAB9ATP53HSD17B10 | |
| SCHEMBL13665112 | 0.81 | HSD17B10 (0.51) | PTGDR2NPC1RAB9ATP53HSD17B10 | |
| SCHEMBL2947402 | 0.81 | PTGDR2 (0.56) | PTGDR2NPC1RAB9ATP53HSD17B10 | |
| SCHEMBL3499253 | 0.81 | PTGDR2 (0.59) | PTGDR2XDHTSHR | |
| SCHEMBL4200563 | 0.81 | ALDH1A1 (0.66) | PTGDR2XDHHPGDALDH1A1 | |
| SCHEMBL4595546 | 0.81 | PTGDR2 (0.68) | PTGDR2HPGDTSHR | |
| SCHEMBL320418 | 0.80 | PTGDR2 (0.66) | PTGDR2KDM4EFFAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | CELLZOME (UK) LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1945646-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Cellzome (UK) Ltd. (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007039467-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | CELLZOME (UK) LTD. (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261946-A1 | Pyrimidine Compounds for the Treatment of Inflammatory Disorders | HRH4, HRH3, HRH2 | PTGDR2 346/4885NPC1 2616/4885RAB9A 3832/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | PTGDR2 2108/4885NPC1 3431/4885RAB9A 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.